DnaJ heat shock protein family (Hsp40) member A4Genealiases: MST104 · MSTP104 · PRO1472
Q-omics provides the consensus-scored DNAJA4 profile across patient tissues and cancer cell-line models. DNAJA4 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DNAJA4 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, DNAJA4 protein abundance shows 23,183 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where DNAJA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJA4 survival associations across molecular data types. DNAJA4 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJA4 RNA expression–survival associations across cancer types. High DNAJA4 expression shows unfavorable associations in UVM, SKCM and LGG, but favorable associations in KIRP, UCEC and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for DNAJA4 RNA expression.
This table summarizes DNAJA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DNAJA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJA4 shows lower tumor expression in KIRC and higher tumor expression in STAD, BRCA, COAD, CHOL and BLCA. The KIRC box plot shows higher DNAJA4 RNA expression in normal versus tumor tissue (log2 FC = −1.181, t-test p < 0.001).
This table shows molecular features associated with DNAJA4 in patient tissues and cancer cell lines. In patient samples, DNAJA4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAJA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
